Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations

Overview of attention for article published in Journal of Thoracic Oncology, May 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter: 18 X users

Readers on

mendeley: 93 Mendeley

So far, Altmetric has seen 24 X posts from 18 X users, with an upper bound of 98,882 followers.

¿Diferencias entre gefitinib, erlotinib, y afatinib en 1ªlinea en Ca d pulmón EGFR mutado?Aquí tenéis un metanálisis! http://t.co/0c705e10os

Current ToC: Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activ... http://t.co/17Cjq1FCLh

Most Popular: Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Acti... http://t.co/17Cjq1FCLh

http://t.co/cCYm2d4pH1 There are no difference in PFS, OS, ORR and DCR among gefitinib, erlotinib, and afatinib. #lungcancer

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 20 additional X posts.